Tissue Engineering Market, By Graft Type (Allografts, Autografts, and Xenografts), By Material Type (Synthetic, Biological, and Others), By Application (Dermal, Orthopedic, Dental, Neurology, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024

Code : CMI2217

Pages :175

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenge – Ineffective Cell Growth, Insufficient and Unstable Production of Growth Factors

Currently available tissue engineering methods face several problems, including ineffective cell growth, insufficient and unstable production of growth factors to stimulate cell communication and proper response, and lack of appropriate biomaterials and techniques to capture appropriate physiological architectures.

Market Opportunity – Increasing Product Approval by Regulatory Authorities

For instance, in June 2023, the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), named Cholederm, received an approval from the Central Drugs Standard Control Organisation (CDSCO) as a Class D medical device. Cholederm is a wound healing material derived from the extracellular matrix of de-cellularised gall bladder of pig and tissue engineered as membrane forms of scaffold, by the researchers at the Division of Experimental Pathology in the Biomedical Technology wing of SCTIMST.